Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) testing services into a 735-bed healthcare facility in the Midwest, enhancing cardiovascular outpatient care [1][3] - The program specifically targets patients with heart failure, hypertension, and other cardiovascular conditions, emphasizing the importance of precise fluid management [2][3] - Daxor's BVA diagnostic provides clinicians with 98% accurate data, facilitating personalized fluid management that improves patient outcomes and reduces costs [3] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, having developed the BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been performed at leading hospital centers across the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - Daxor is involved in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care with the U.S. Department of Defense [4]
Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center